This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Di Bacco, A. Articles by Cotter, T. G. Search for Related Content PubMed PubMed Citation Articles by Di Bacco, A. Articles by Cotter, T. G.

Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis

Tumour Biology Laboratory, Department of Biochemistry, University College Cork, Cork, Ireland

Correspondence: Thomas G. Cotter, D.Phil., Tumour Biology Laboratory, Department of Biochemistry, University College Cork, Cork, Ireland. Telephone: 353-21-904068; Fax: 353-21-904259; e-mail: t.cotter{at}ucc.ie

ABSTRACT

Chronic myeloid leukemia (CML) is a disease of the hematopoietic system, characterized by the presence of the Bcr-Abl oncoprotein. The main characteristics of this disease include adhesion independence, growth factor independence, and resistance to apoptosis. Loss or mutation of the tumor suppressor gene, p53, is one of the most frequent secondary mutations in CML blast crisis. The transition between chronic phase and blast crisis is associated with increased resistance to apoptosis correlating with poor prognosis. This review focuses on the involvement of these two oncoproteins in the development and progression of the apoptotic-resistant phenotype in CML.

Key Words. Leukemia • Bcr-Abl • p53 • Apoptosis

This article has been cited by other articles:

				S. Grosso, A. Puissant, M. Dufies, P. Colosetti, A. Jacquel, K. Lebrigand, P. Barbry, M. Deckert, J. P. Cassuto, B. Mari, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors Mol. Cancer Ther., July 1, 2009; 8(7): 1924 - 1933. [Abstract] [Full Text] [PDF]

				T. Motiwala, S. Majumder, K. Ghoshal, H. Kutay, J. Datta, S. Roy, D. M. Lucas, and S. T. Jacob PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells J. Biol. Chem., January 2, 2009; 284(1): 455 - 464. [Abstract] [Full Text] [PDF]

				J. G. Harb, B. I. Chyla, and C. S. Huettner Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis Blood, April 1, 2008; 111(7): 3760 - 3769. [Abstract] [Full Text] [PDF]

				S. Wong, J. McLaughlin, D. Cheng, and O. N. Witte Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors Blood, May 15, 2003; 101(10): 4088 - 4097. [Abstract] [Full Text] [PDF]

				M. Nieborowska-Skorska, G. Hoser, P. Kossev, M. A. Wasik, and T. Skorski Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis Blood, May 29, 2002; 99(12): 4531 - 4539. [Abstract] [Full Text] [PDF]

				A. W. Goetz, H. van der Kuip, R. Maya, M. Oren, and W. E. Aulitzky Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells Cancer Res., October 1, 2001; 61(20): 7635 - 7641. [Abstract] [Full Text] [PDF]

				E. Kolomietz, J. Al-Maghrabi, S. Brennan, J. Karaskova, S. Minkin, J. Lipton, and J. A. Squire Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis Blood, June 1, 2001; 97(11): 3581 - 3588. [Abstract] [Full Text] [PDF]